肝转移NET患者动脉内与标准静脉给予镥-177-DOTA-奥曲肽的多中心随机对照试验方案(LUTIA试验)
LUTIA试验为多中心、患者内随机对照试验,计划纳入26例进展性、肝主导、不可切除的I或II级NET患者。双叶 bulky 病变患者随机接受左或右肝动脉IA给药,对侧肝叶接受IV给药作为二次通过效应。主要终点为治疗后SPECT/CT上两肝叶间177Lu-DOTATATE摄取的肿瘤/非肿瘤比值差异(IA vs IV)。
要点
- LUTIA试验采用患者内随机设计,比较IA与IV给予177Lu-DOTATATE在肝转移灶中的摄取差异。
- 主要终点为治疗后SPECT/CT上两肝叶肿瘤/非肿瘤摄取比值差异。
- 次要终点包括两肝叶吸收剂量、肿瘤反应、剂量-反应关系、毒性、肝外病灶摄取及肾脏摄取。
核心结论
- 该试验将探究IA给予177Lu-DOTATATE是否较IV给药在肝转移灶中产生更高的放射性浓度。
研究设计与样本
- 多中心、患者内随机对照试验,计划纳入26例进展性、肝主导、不可切除的I或II级NET患者。
- 双叶 bulky 病变患者随机分配至左或右肝动脉IA治疗,对侧肝叶接受IV治疗作为二次通过效应。
关键数值与推荐
- 主要终点为治疗后SPECT/CT上两肝叶间177Lu-DOTATATE摄取的肿瘤/非肿瘤比值差异(IA vs IV)。
- 次要终点包括两肝叶吸收剂量、肿瘤反应、剂量-反应关系、毒性、肝外病灶摄取及肾脏摄取。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lutetium-177-DOTA-octreotate (177Lu-DOTATATE) significantly increases survival and response rates in patients with grade I and grade II neuroendocrine tumors (NETs). However, survival and response rates are significantly lower in patients with bulky liver metastases. Increasing the tumor-absorbed dose in liver metastases may improve response to 177Lu-DOTATATE. The LUTIA (Lutetium Intra-Arterial) study aims to increase the tumor-absorbed dose in liver metastases by intra-arterial (IA) administration of 177Lu-DOTATATE, compared to conventional intravenous (IV) administration. METHODS: A multicenter, within-patient randomized controlled trial (RCT) in 26 patients with progressive, liver-dominant, unresectable grade I or grade II NET will be conducted. Patients with bilobar bulky disease will be randomly allocated to receive IA treatment into either the left or the right hepatic artery. Using this approach, one liver lobe will be treated intra-arterially (first-pass effect), while the contralateral lobe will receive an intravenous treatment as a second-pass effect. The primary endpoint of this study is the difference in tumor-to-non-tumor ratio of 177Lu-DOTATATE uptake between the two liver lobes on post-treatment SPECT/CT (IA versus IV). Secondary endpoints include absorbed dose in both liver lobes, tumor response, dose-response relationship, toxicity, uptake in extrahepatic lesions, and renal uptake. DISCUSSION: This multicenter, within-patient RCT will investigate whether IA administration of 177Lu-DOTATATE results in a higher activity concentration in liver metastases compared to IV administration. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03590119. Registered on 17 July 2018.
引用
- Ebbers SC, Braat AJAT, Moelker A, et al. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials. 2020. PMID: 32024533. doi:10.1186/s13063-019-3888-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。